Intraperitoneal Injection of Oncolytic Viruses H101 for Patients With

Clinical Trial Description

This study is to evaluate the effectiveness of local immune activation, and safety in patients with refractory malignant ascites after Intraperitoneal injection of oncolytic Viruses H101. ;

Study Design

See also
Status	Clinical Trial	Phase
Recruiting	`NCT01852409` - Phase I Trial of Intraperitoneal Bevacizumab in Refractory Malignant Ascites	Phase 1
Withdrawn	`NCT02477657` - Palliative Care Outcomes in the Management of Malignant Ascites by Interventional Radiology
Completed	`NCT02891369` - Analysis of Patients Treated With Bevacizumab Intraperitoneal for the Treatment of Refractory Malignant Ascites
Recruiting	`NCT05303844` - Oncolytic Virotherapy Plus PD-1 Inhibitor for Patients With Refractory Malignant Ascites	Phase 1

See also

Status

Clinical Trial

Phase

Recruiting

NCT01852409 - Phase I Trial of Intraperitoneal Bevacizumab in Refractory Malignant Ascites

Phase 1

Withdrawn

NCT02477657 - Palliative Care Outcomes in the Management of Malignant Ascites by Interventional Radiology

Completed

NCT02891369 - Analysis of Patients Treated With Bevacizumab Intraperitoneal for the Treatment of Refractory Malignant Ascites

Recruiting

NCT05303844 - Oncolytic Virotherapy Plus PD-1 Inhibitor for Patients With Refractory Malignant Ascites

Phase 1

Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.

Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.

Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

NCT number	NCT04771676
Study type	Interventional
Source	Fudan University
Contact
Status	Completed
Phase	Phase 2
Start date	March 5, 2021
Completion date	January 31, 2023

Intraperitoneal Injection of Oncolytic Viruses H101 for Patients With Refractory Malignant Ascites

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms